FDA Patient Affairs Office Needed To Improve Conflict Of Interest, NORD Says
Executive Summary
Elevating FDA's handling of patient-related issues could help ensure more patients get on advisory committees, rare disease advocates say, but agency notes that waivers are always an option.
You may also be interested in...
FDA Safety Meetings: Outpatient Drugs, Hypoglycemia Getting Limelight
US agency's events could address a touchy subject: how much responsibility does FDA have for preventing adverse events, and how much falls to physicians?
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.